These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 7231329

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Pharmacology and mechanism of action of etofibrate].
    Schatton W.
    Med Welt; 1982 Sep 24; 33(38):1310-4. PubMed ID: 6752630
    [No Abstract] [Full Text] [Related]

  • 6. [Pharmacologic therapy of arteriosclerosis: current possibilities].
    Priego JG, Díaz Méndez M.
    Med Clin (Barc); 1984 Oct 06; 83(10):431-2. PubMed ID: 6503408
    [No Abstract] [Full Text] [Related]

  • 7. [Use of etofibrate in the treatment of patients with hyperlipidemia and arteriosclerosis obliterans of the legs].
    Dembińska-Kieć A, Kostka-Trabka E, Grodzińska L, Bieroń K, Kedzior A, Basista M, Zmuda A, Trabka E, Sławiński M, Czarnecka B.
    Pol Tyg Lek; 1984 Oct 06; 42(51-52):1643-8. PubMed ID: 3330798
    [No Abstract] [Full Text] [Related]

  • 8. The effect of Etofibrate (Lipo-Merz) on "in vitro" cellular immune response and on lipid parameters of men with myocardial infarction and with arteriosclerosis obliterans.
    Horváth M, Varsányl M, Jovanovich N, Romics L, Gerö S.
    Allergol Immunopathol (Madr); 1990 Oct 06; 18(2):95-9. PubMed ID: 2371944
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis.
    Betz E, Quack G.
    Vasa; 1990 Oct 06; 19(2):157-60. PubMed ID: 2371790
    [Abstract] [Full Text] [Related]

  • 11. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ, Padró T, Cánovas M, Vidal M, Villaverde CA.
    Methods Find Exp Clin Pharmacol; 1983 Nov 06; 5(9):613-7. PubMed ID: 6668971
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Lipid therapy with etofibrate. Reduction of multiple risk factors with an active substance. Report of an international seminar. 8-11 November 1989, Houston, Texas].
    Fortschr Med Suppl; 1990 Nov 06; 85():1-15. PubMed ID: 2338325
    [No Abstract] [Full Text] [Related]

  • 15. [Study of the antilipemic effect of etofibrate (Lipo-Merz)].
    Słowińska R, Bochenek W, Unlot J.
    Pol Tyg Lek; 1983 Apr 25; 38(17):529-32. PubMed ID: 6356087
    [No Abstract] [Full Text] [Related]

  • 16. [Etofibrate in severe diet-refractory cases of hyperlipoproteinemia].
    Schatton W, Holm E.
    Fortschr Med; 1986 Apr 03; 104(13):280-2. PubMed ID: 3699655
    [No Abstract] [Full Text] [Related]

  • 17. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981 Apr 03; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 18. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 19. [Experimental research on the action of a derivative from a p-chloropenoxyisobutyric acid series on lipid parameters].
    Filip M, Hriscu A, Păduraru I, Rusu M.
    Rev Med Chir Soc Med Nat Iasi; 1986 Jan 15; 90(1):156-60. PubMed ID: 3764166
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.